THERAPY OF INTERSTITIAL LUNG DISEASE AGAINST THE BACKGROUND OF SOME SYSTEMIC AUTOIMMUNE DISEASES


D.V. Bestaev, E.L. Nasonov

FSBI "SRIR n.a. V.A.Nasonova" RAMS
Systemic autoimmune diseases (SAD) include a heterogeneous group of immune-mediated inflammatory diseases characterized by the development of multi-organ failure. Patients with SAD can experience interstitial lung disease (ILD). High-resolution computed tomography of the lungs and pulmonary function test play a leading role in the diagnosis of ILD. To date, despite the progress in addressing issues of pathogenesis and diagnosis of ILD in SAD, there is no effective immunomodulatory therapy for ILD-SAD. The therapy of ILD is aimed to the suppressing immune inflammatory process. This article discusses the effectiveness of the immunosuppressive therapy in some SAD.

About the Autors


D.V. Bestaev - Researcher at the FSBI "SRIR n.a. V.A. Nasonova" RAMS; e-mail: davidbestaev@rambler.ru
E.L. Nasonov – MD, Prof., Acad.of RAS, Head of the Department of Rheumatology FPGPEP SBEI HPE "First MSMU n.a. I.M. Sechenov" of RMPH, Director of FSBI "SRIR n.a. V.A. Nasonova" RAMS


Similar Articles


Бионика Медиа